News

First Patient Dosed in Trial of Phage Therapy for Lung Infections

The first patient has been dosed in a Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, an investigational bacteriophage therapy, in adult cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa lung infections. The PHAGE trial (NCT05453578) is recruiting an estimated 72 such patients who tested positive for a P. aeruginosa infection…

ReCode’s mRNA Therapy Wins $15M CF Foundation Investment

The Cystic Fibrosis Foundation is investing up to $15 million in ReCode Therapeutics to support the development of the company’s inhaled mRNA-based therapy for cystic fibrosis (CF). “We are excited to expand our relationship with the CF Foundation with this investment in our CFTR mRNA program for cystic…

Renexxion Seeks FDA OK to Test Naronapride for GI Problems in CF

Renexxion is seeking clearance from the U.S. Food and Drug Administration (FDA) for clinical testing of the treatment candidate naronapride in people with cystic fibrosis (CF) and gastrointestinal (GI) problems. The Ireland-based biopharmaceutical company, which specializes in treatments for gastrointestinal disorders, announced the opening of an investigational new…

Top 10 Cystic Fibrosis Stories of 2022

Cystic Fibrosis News Today brought you daily coverage of the latest scientific discoveries, treatment advances, and clinical trials related to cystic fibrosis (CF) this past year. We look forward to continuing to offer you the most up-to-date information in 2023. Here are the 10 most-read CF news articles of 2022,…